SPRO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SP

Mkt Cap

$64.3M

Volume

343.96K

Next Earnings

November 12th

Loading chart

SP

SPROSpero Therapeutics, Inc. Common Stock

SPRO

Pay with—

Available Balance0.00

SP

Mkt Cap

$65.8M

Volume

343.96K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsightThe complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market.GlobeNewswire Inc. · Oct 12, 2026

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L AntibodySpero Therapeutics and Innovent Biologics announced an exclusive license agreement for SP001 (IBI355), a third-generation anti-CD40L antibody. Spero receives global rights excluding Greater China, with potential milestone payments totaling approximately $1.1 billion plus tiered royalties. Spero plans to initiate a Phase 2 trial in IgG4-related disease in Q2 2027, while Innovent will pursue a Phase 2 trial in Sjögren's disease in China by early 2027.GlobeNewswire Inc. · Jul 14, 2026

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIsGSK and Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for treating complicated urinary tract infections including pyelonephritis. The drug demonstrated non-inferiority to intravenous imipenem-cilastatin in Phase 3 trials and is expected to launch in the U.S. by end of 2026, offering an alternative to hospital-based IV treatments for the 3+ million Americans annually affected by cUTIs.Benzinga · Jun 17, 2026

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Spero Therapeutics granted 90,000 restricted stock unit awards to a new employee under their 2019 Inducement Equity Incentive Plan, with vesting occurring in four equal annual installments starting December 1, 2025.GlobeNewswire Inc. · Nov 28, 2025

Spero Therapeutics Provides Business Update and Announces Interim Leadership ChangesSpero Therapeutics announced interim leadership changes, including the appointment of Esther Rajavelu as Interim President and CEO, and Frank Thomas as Chairman of the Board. The company also provided updates on the Phase 3 PIVOT-PO trial of Tebipenem HBr and its financial position.GlobeNewswire Inc. · Jan 10, 2025

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswireSpero Therapeutics, a biopharmaceutical company, announced the grant of 227,500 restricted stock unit awards to new employees under its 2019 Inducement Equity Incentive Plan. The RSUs will vest over four years, subject to continued employment.GlobeNewswire Inc. · Jul 3, 2024

Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.Zacks Investment Research · Jun 24, 2024

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of 116,667 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Jun 3, 2024

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor ConferenceCAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY. Details are as follows:GlobeNewswire Inc. · May 16, 2024

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business UpdateCAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial and operational results for the quarter ended March 31, 2024.GlobeNewswire Inc. · May 15, 2024

to start trading

SP

SPROSpero Therapeutics, Inc. Common Stock

SPRO

Pay with—

Available Balance0.00

Your PositionYou don't own any SPRO yet.

Related Tickers

Earnings